Michael Hickey has broad expertise in oncology and rare disease clinical drug development, especially focused on challenging indications such as head-and-neck cancer, colorectal cancer, breast cancer with BRCA mutations as well as program development for chemotherapy induced myelosuppression, hemophilia, and Battens Disease. At Bio-Path Holdings, Mr. Hickey will be responsible for development, implementation and oversight of the company’s ongoing and planned trials. Mr. Hickey has held positions of increasing responsibility at Amgen, BioMarin, PPD and G1 Therapeutics, where he managed domestic and global drug development programs from their earliest clinical stages through regulatory submission. His experience in clinical development includes the regulatory approval of Brineura®, Kepivance®, and post-marketing development of Neupogen®/Neulasta®. In addition to his career activities, Mr. Hickey is a member of the Project Management Institute (PMI) and the Drug Information Association (DIA) the foremost professional organization in this field, responsible for setting standards for professional competence and promoting excellence in project management and drug development. Mr. Hickey earned his Bachelor of Science from the University of Southern California and an MBA from California State University at San Marcos.
